Log In
Print this Print this

CD200 mAb

  Manage Alerts
Collapse Summary General Information
Company Trillium Therapeutics Inc.
DescriptionCD200 mAb
Molecular Target CD200
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today